FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.
FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections
Monday, January 27, 2014
FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment